A basic peptide derived from the HARP C-terminus inhibits anchorage-independent growth of DU145 prostate cancer cells

Experimental Cell Research

Volumn 313, Issue 19, 2007, Pages 4041-4050

  Bermek, Oya ^a   Diamantopoulou, Zoi ^b   Polykratis, Apostolis ^b   Dos Santos, Celia ^a   Hamma Kourbali, Yamina ^a   Burlina, Fabienne ^c   Delbé, Jean ^a   Chassaing, Gerard ^c   Fernig, David G ^d   Katsoris, Pagnagiotis ^b   Courty, José ^a  

^a CNRS   (France)

^b UNIVERSITY OF PATRAS   (Greece)

^c Centre National de la Recherche Scientifique   (France)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Anchorage independent growth; Basic peptide; Heparin affin regulatory peptide; Prostate cancer; Receptor protein tyrosine phosphatase

Indexed keywords

HEPARIN AFFIN REGULATORY PEPTIDE; HEPARIN BINDING PROTEIN; PROTEIN TYROSINE PHOSPHATASE; PROTEIN[122-131]; RECEPTOR PROTEIN TYROSINE PHOSPHATASE BETA; RECEPTOR PROTEIN TYROSINE PHOSPHATASE ZETA; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; BINDING SITE; BIOTINYLATION; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; CELL SURFACE; CONTROLLED STUDY; DRUG BINDING; DRUG EFFECT; DRUG INHIBITION; HUMAN; HUMAN CELL; MITOGENESIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

EID: 35448969369     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2007.07.032     Document Type: Article

References (37)

1. Gronberg H. Prostate cancer epidemiology. Lancet 361 (2003) 859-864
2. Bostwick D.G., and Qian J. Effect of androgen deprivation therapy on prostatic intraepithelial neoplasia. Urology 58 (2001) 91-93
3. Feldman B.J., and Feldman D. The development of androgen-independent prostate cancer. Nat. Rev., Cancer 1 (2001) 34-45
4. Chauhan A.K., Li Y.S., and Deuel T.F. Pleiotrophin transforms NIH 3T3 cells and induces tumors in nude mice. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 679-682
5. Choudhuri R., Zhang H.T., Donnini S., Ziche M., and Bicknell R. An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis. Cancer Res. 57 (1997) 1814-1819
6. Courty J., Dauchel M.C., Caruelle D., Perderiset M., and Barritault D. Mitogenic properties of a new endothelial cell growth factor related to pleiotrophin. Biochem. Biophys. Res. Commun. 180 (1991) 145-151
7. Czubayko F., Schulte A.M., Berchem G.J., and Wellstein A. Melanoma angiogenesis and metastasis modulated by ribozyme targeting of the secreted growth factor pleiotrophin. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 14753-14758
8. Papadimitriou E., Polykratis A., Courty J., Koolwijk P., Heroult M., and Katsoris P. HARP induces angiogenesis in vivo and in vitro: implication of N or C terminal peptides. Biochem. Biophys. Res. Commun. 282 (2001) 306-313
9. Grzelinski M., Bader N., Czubayko F., and Aigner A. Ribozyme-targeting reveals the rate-limiting role of pleiotrophin in glioblastoma. Int. J. Cancer 117 (2005) 942-951
10. Stoica G.E., Kuo A., Aigner A., Sunitha I., Souttou B., Malerczyk C., Caughey D.J., Wen D., Karavanov A., Riegel A.T., and Wellstein A. Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. J. Biol. Chem. 276 (2001) 16772-16779
11. Raulo E., Chernousov M.A., Carey D.J., Nolo R., and Rauvala H. Isolation of a neuronal cell surface receptor of heparin binding growth-associated molecule (HB-GAM). Identification as N-syndecan (syndecan-3). J. Biol. Chem. 269 (1994) 12999-13004
12. Maeda N., Nishiwaki T., Shintani T., Hamanaka H., and Noda M. 6B4 proteoglycan/phosphacan, an extracellular variant of receptor-like protein-tyrosine phosphatase zeta/RPTPbeta, binds pleiotrophin/heparin-binding growth-associated molecule (HB-GAM). J. Biol. Chem. 271 (1996) 21446-21452
13. Bernard-Pierrot I., Delbe J., Rouet V., Vigny M., Kerros M.E., Caruelle D., Raulais D., Barritault D., Courty J., and Milhiet P.E. Dominant negative effectors of heparin affin regulatory peptide (HARP) angiogenic and transforming activities. J. Biol. Chem. 277 (2002) 32071-32077
14. Czubayko F., Riegel A.T., and Wellstein A. Ribozyme-targeting elucidates a direct role of pleiotrophin in tumor growth. J. Biol. Chem. 269 (1994) 21358-21363
15. Soulie P., Heroult M., Bernard I., Kerros M.E., Milhiet P.E., Delbe J., Barritault D., Caruelle D., and Courty J. Immunoassay for measuring the heparin-binding growth factors HARP and MK in biological fluids. J. Immunoass. Immunochem. 23 (2002) 33-48
16. Hatziapostolou M., Delbe J., Katsoris P., Polytarchou C., Courty J., and Papadimitriou E. Heparin affin regulatory peptide is a key player in prostate cancer cell growth and angiogenicity. Prostate 65 (2005) 151-158
17. Vacherot F., Caruelle D., Chopin D., Gil-Diez S., Barritault D., Caruelle J.P., and Courty J. Involvement of heparin affin regulatory peptide in human prostate cancer. Prostate 38 (1999) 126-136
18. Lu K.V., Jong K.A., Kim G.Y., Singh J., Dia E.Q., Yoshimoto K., Wang M.Y., Cloughesy T.F., Nelson S.F., and Mischel P.S. Differential induction of glioblastoma migration and growth by two forms of pleiotrophin. J. Biol. Chem. 280 (2005) 26953-26964
19. Y. Hamma-Kourbali, I. Bernard-Pierrot, M. Heroult, S. Dalle, D. Caruelle, P.E. Milhiet, D.G. Fernig, J. Delbe, J. Courty, Inhibition of the mitogenic, angiogenic and tumorigenic activities of pleiotrophin by a synthetic peptide corresponding to its C-thrombospondin repeat-I domain, J. Cell Physiol. (in press).
20. Heroult M., Bernard-Pierrot I., Delbe J., Hamma-Kourbali Y., Katsoris P., Barritault D., Papadimitriou E., Plouet J., and Courty J. Heparin affin regulatory peptide binds to vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. Oncogene 23 (2004) 1745-1753
21. Bernard-Pierrot I., Delbe J., Caruelle D., Barritault D., Courty J., and Milhiet P.E. The lysine-rich C-terminal tail of heparin affin regulatory peptide is required for mitogenic and tumor formation activities. J. Biol. Chem. 276 (2001) 12228-12234
22. Barbosa I., Garcia S., Barbier-Chassefiere V., Caruelle J.P., Martelly I., and Papy-Garcia D. Improved and simple micro assay for sulfated glycosaminoglycans quantification in biological extracts and its use in skin and muscle tissue studies. Glycobiology 13 (2003) 647-653
23. Dong Z., and Cmarik J.L. Harvesting cells under anchorage-independent cell transformation conditions for biochemical analyses. Sci. STKE (2002) PL7
24. Vacherot F., Delbe J., Heroult M., Barritault D., Fernig D.G., and Courty J. Glycosaminoglycans differentially bind HARP and modulate its biological activity. J. Biol. Chem 274 (1999) 7741-7747
25. Rahmoune H., Rudland P.S., Gallagher J.T., and Fernig D.G. Hepatocyte growth factor/scatter factor has distinct classes of binding site in heparan sulfate from mammary cells. Biochemistry 37 (1998) 6003-6008
26. Rahmoune H., Chen H.L., Gallagher J.T., Rudland P.S., and Fernig D.G. Interaction of heparan sulfate from mammary cells with acidic fibroblast growth factor (FGF) and basic FGF. Regulation of the activity of basic FGF by high and low affinity binding sites in heparan sulfate. J. Biol. Chem. 273 (1998) 7303-7310
27. Maeda N., and Noda M. Involvement of receptor-like protein tyrosine phosphatase zeta/RPTP beta and its ligand pleiotrophin/heparin-binding growth-associated molecule (HB-GAM) in neuronal migration. J. Cell. Biol. 142 (1998) 203-216
28. Hatziapostolou M., Polytarchou C., Katsoris P., Courty J., and Papadimitriou E. Heparin affin regulatory peptide/pleiotrophin mediates fibroblast growth factor 2 stimulatory effects on human prostate cancer cells. J. Biol. Chem. 281 (2006) 32217-32226
29. Muller S., Kunkel P., Lamszus K., Ulbricht U., Lorente G.A., Nelson A.M., von Schack D., Chin D.J., Lohr S.C., Westphal M., and Melcher T. A role for receptor tyrosine phosphatase zeta in glioma cell migration. Oncogene 22 (2003) 6661-6668
30. Goldmann T., Otto F., and Vollmer E. A receptor-type protein tyrosine phosphatase PTP zeta is expressed in human cutaneous melanomas. Folia Histochem. Cytobiol. 38 (2000) 19-20
31. Kilpelainen I., Kaksonen M., Avikainen H., Fath M., Linhardt R.J., Raulo E., and Rauvala H. Heparin-binding growth-associated molecule contains two heparin-binding beta -sheet domains that are homologous to the thrombospondin type I repeat. J. Biol. Chem. 275 (2000) 13564-13570
32. Meng K., Rodriguez-Pena A., Dimitrov T., Chen W., Yamin M., Noda M., and Deuel T.F. Pleiotrophin signals increased tyrosine phosphorylation of beta beta-catenin through inactivation of the intrinsic catalytic activity of the receptor-type protein tyrosine phosphatase beta/zeta. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 2603-2608
33. Pariser H., Perez-Pinera P., Ezquerra L., Herradon G., and Deuel T.F. Pleiotrophin stimulates tyrosine phosphorylation of beta-adducin through inactivation of the transmembrane receptor protein tyrosine phosphatase beta/zeta. Biochem. Biophys. Res. Commun. 335 (2005) 232-239
34. Pariser H., Ezquerra L., Herradon G., Perez-Pinera P., and Deuel T.F. Fyn is a downstream target of the pleiotrophin/receptor protein tyrosine phosphatase beta/zeta-signaling pathway: regulation of tyrosine phosphorylation of Fyn by pleiotrophin. Biochem. Biophys. Res. Commun. 332 (2005) 664-669
35. Foehr E.D., Lorente G., Kuo J., Ram R., Nikolich K., and Urfer R. Targeting of the receptor protein tyrosine phosphatase beta with a monoclonal antibody delays tumor growth in a glioblastoma model. Cancer Res. 66 (2006) 2271-2278
36. Ulbricht U., Eckerich C., Fillbrandt R., Westphal M., and Lamszus K. RNA interference targeting protein tyrosine phosphatase zeta/receptor-type protein tyrosine phosphatase beta suppresses glioblastoma growth in vitro and in vivo. J. Neurochem. 98 (2006) 1497-1506
37. Polykratis A., Katsoris P., Courty J., and Papadimitriou E. Characterization of heparin affin regulatory peptide signaling in human endothelial cells. J. Biol. Chem. 280 (2005) 22454-22461